BioSpace News Archive

Drug Development

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces Completion of Enrollment of its Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression

NRx Pharmaceuticals, Inc. today announced completion of enrollment in its Phase 2b/3 study of NRX-101, the Company’s patented combination of the NMDA antagonist D-cycloserine and lurasidone, in Suicidal Treatment Resistant Bipolar Depression.

January 22, 2024
·
4 min read
Drug Development

Mallinckrodt Presents New Data on TERLIVAZ® (terlipressin) for Injection at the Society of Critical Care Medicine (SCCM) 2024 Critical Care Congress

Mallinckrodt plc, a global specialty pharmaceutical company, today announced the presentation of findings from a post hoc analysis of the Phase 3 CONFIRM clinical trial.

January 22, 2024
·
8 min read
Genetown

ProteinLogic and Stellenbosch University receive $1.3 million grant to develop blood test to monitor response to TB antimicrobial chemotherapy

ProteinLogic announced that they have received a $1.35 million grant from the Bill & Melinda Gates Foundation to accelerate the development of ImmiPrint® Technology to monitor treatment responses to TB antimicrobial chemotherapy.

January 22, 2024
·
7 min read
Business

NMD Pharma Appoints Morten Bull as SVP, General Counsel and Head of People & Business Services

NMD Pharma A/S, a clinical-stage biotech dedicated to developing novel and improved treatments for patients living with neuromuscular diseases, announces the appointment of Morten Bull as Senior Vice President, General Counsel and Head of People & Business Services with effect from 1 January 2024.

January 22, 2024
·
3 min read
AC Immune to Regain Global Rights to Crenezumab and Semorinemab

AC Immune to Regain Global Rights to Crenezumab and Semorinemab Company’s strategy is focused on advancing the Phase 2 development of its three active immunotherapies Active immunotherapy now considered to be the optimal approach for precision prevention of neurodegenerative diseases.

January 22, 2024
·
6 min read
Business

Neumora Therapeutics Appoints Kaya Pai Panandiker as Chief Commercial Officer

Neumora Therapeutics, Inc. today announced the appointment of Kaya Pai Panandiker as chief commercial officer and a member of Neumora’s executive team, reporting to Henry Gosebruch, president and chief executive officer.

January 22, 2024
·
4 min read
Business

Apnimed Announces New Leadership Appointments as the Company Builds Its Commercial and Human Resource Capabilities in Support of AD109, a Potential Nighttime Oral Treatment for Obstructive Sleep Apnea

Apnimed, Inc. announced Graham Goodrich has joined the company as Chief Commercial Officer and Ted Harding as Chief Human Resources Officer.

January 22, 2024
·
6 min read
BioMidwest

Kraig Biocraft Laboratories Targets Vertical Markets for its Spider Silk and Shares Planned Applications

Kraig Biocraft Laboratories, Inc., shares an update on near-term commercial applications and opportunities for recombinant spider silk as the Company prepares for expanding production in 2024.

January 22, 2024
·
3 min read
Drug Development

Cara Therapeutics Prioritizes Late-Stage Notalgia Paresthetica Program and Extends Cash Runway into 2026

Cara Therapeutics, Inc. today announced it will focus its resources on the oral difelikefalin Phase 2/3 clinical program in notalgia paresthetica (NP) and significantly reduce its operating expenses.

January 22, 2024
·
6 min read
ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine

ProMIS Neurosciences Inc. today announced the selection of a lead vaccine candidate, PMN400, against multiple synucleinopathies including Multiple System Atrophy (MSA), Parkinson’s disease and Lewy Body Dementia.

January 22, 2024
·
5 min read